
Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target
Alnylam Pharmaceuticals (ALNY) Analyst Ratings
Bulls say
Alnylam Pharmaceuticals is viewed positively because its commercial TTR franchise is still expanding rapidly, with Q3 net product revenue of $1.3B, Amvuttra revenue of $1.13B, and strong US demand growth that leaves substantial untreated patient runway in TTR-CM. Its outlook is further supported by a deep pipeline, led by nucresiran’s differentiated Q6M dosing and stronger knockdown, plus advancing programs in neuroscience and bleeding disorders that could add meaningful long-term growth. Even with 340B and other reimbursement uncertainties, the company ended Q3 with $3.6B in cash and appears positioned to convert clinical execution into durable margin expansion and franchise durability.
Bears say
Alnylam Pharmaceuticals is facing a weaker fundamental setup as management sees no acceleration in 4Q demand, with FY TTR revenue tracking toward the low end of the $4.2B-$4.4B range and Q3 Amvuttra revenue of $1.13B only masking slowing US growth. New UnitedHealthcare Medicare Advantage restrictions starting October 1 and potential 340B reform create payer and reimbursement uncertainty, while gross margin already fell to 72% from 75% in Q2 due to a higher Amvuttra royalty burden. The firm has also reduced FY27 Amvuttra sales estimates by ~12% and peak sales to $8B from ~$10B, leaving limited visibility into sustainable growth despite the broader RNAi pipeline.
This aggregate rating is based on analysts' research of Alnylam Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Alnylam Pharmaceuticals (ALNY) Analyst Forecast & Price Prediction
Start investing in Alnylam Pharmaceuticals (ALNY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Alnylam Pharmaceuticals (ALNY) Forecast
Alnylam Pharmaceuticals (ALNY) Analyst Forecast & Price Prediction
Start investing in Alnylam Pharmaceuticals (ALNY)
Order type
Buy in
Order amount
Est. shares
0 shares